Icotinib, a first-generation EGFR TKI, is being evaluated in a targeted population of advanced non-small cell lung cancer (NSCLC) patients with uncommon EGFR mutations. This study addresses a significant unmet need in the NSCLC market, particularly as existing therapies primarily target common mutations (e.g., 19 del and 21 L858R). The potential efficacy of icotinib in this niche could position it favorably against competitors, especially in regions where access to newer agents is limited. Given the estimated enrollment of 30 patients and the focus on a specific mutation profile, the results could provide critical insights into the drug's viability and market potential, particularly in Asian markets where icotinib is already established.